Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.

British journal of cancer - 9 May 2017

Janssen A, Verkleij C P M, van der Vlist A, Mathijssen R H J, Bloemendal H J, Ter Heine R

Abstract excerpt

BACKGROUND: Cabazitaxel is approved for treatment of castration-resistant metastatic prostate cancer. The current dosing strategy of cabazitaxel is based on body surface area (BSA). Body surface area is known as a poor predictor for total systemic exposure to drugs, since it does not take into account variability in activity of metabolising enzymes, necessary for clearance of drugs. As exposure to cabazitaxel is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Anti-Anxiety Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma

Share to Cytochrome P-450 CYP3A

Share to Midazolam

Share to Prostatic Neoplasms, Castration-Resistant

Share to Taxoids

Source

Open in PubMed Open full text

Identifiers

PMID: 28399110
DOI: 10.1038/bjc.2017.91
PMCID: PMC5482735

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.PMID 28399110Read ↗

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.Semantic proximity Read ↗

CYP3A activity: towards dose adaptation to the individual.Semantic proximity Read ↗

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.Semantic proximity Read ↗

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients.Semantic proximity Read ↗

Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.Semantic proximity Read ↗

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.Semantic proximity Read ↗

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.Semantic proximity Read ↗

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.Semantic proximity Read ↗

Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.Semantic proximity Read ↗

Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.Semantic proximity Read ↗

Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.